每经AI快讯，美中嘉和(02453.HK)高开逾6%，截至发稿涨6.12%，报2.08港元，成交额10.07万港元。 ...

Core Viewpoint - The stock of Meizhong Jiahe (02453) opened over 6% higher following the approval of its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Pass" designated medical institution list [1] Group 1: Company Developments - Meizhong Jiahe's stock rose by 6.12%, reaching HKD 2.08, with a trading volume of HKD 100,700 [1] - The approval allows Guangzhou Taihe Oncology Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, enhancing its competitive advantage in the oncology field [1] Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Pass" is a key initiative under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] - Designated medical institutions in the Greater Bay Area can leverage special pharmaceutical policies, allowing them to access advanced medical solutions [1] - The initiative aims to broaden the business scope of qualified institutions and provide urgently needed medications to more oncology patients, thereby strengthening the overall competitive landscape in the oncology medical sector [1]

Core Viewpoint - Meizhong Jiahe (02453) has received approval for its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its competitive advantage in the oncology field [2][4]. Group 1: Company Developments - Meizhong Jiahe's stock price increased by 8.67%, reaching HKD 2.13, with a trading volume of HKD 664,600 [2][4]. - The approval allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [2][4]. - This qualification positions the company as a specialized oncology medical institution with the capability to introduce innovative drugs and devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [2][4]. Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key implementation measure of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [2][4]. - The initiative aims to facilitate the use of clinically necessary drugs and advanced medical devices in designated institutions within the Greater Bay Area, enhancing healthcare access for patients [2][4].

Core Viewpoint - Meizhong Jiahe (02453) has seen a significant stock price increase of 6.12%, reaching HKD 2.08, following the announcement of its subsidiary Guangzhou Taihe Oncology Hospital being approved to enter the "Hong Kong-Macao Drug and Medical Device Access" list, enhancing its competitive edge in the oncology sector [1] Group 1 - The approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [1] - The initiative is part of the core implementation measures of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan," which aims to facilitate the use of clinical urgently needed drugs and advanced medical devices in designated medical institutions [1]

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1: Regulatory Approval - Guangzhou Taihe Oncology Hospital received approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration on December 8, 2025, to be included in the designated medical institution list for the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key measure under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] Group 2: Business Expansion - The qualification allows the company to import and use urgently needed drugs and advanced medical devices that have been approved in Hong Kong and Macao but not yet in mainland China [1] - This move will enable the company to introduce innovative oncology drugs and expand its business boundaries, creating a differentiated competitive advantage in the oncology market [1] Group 3: Clinical and Research Enhancement - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, improving clinical diagnosis and treatment levels as well as research capabilities [1] - By introducing cutting-edge medical devices and optimizing oncology treatment plans, the company aims to align with international medical standards and enhance the overall patient service experience and treatment outcomes [1]

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1 - The approval was granted by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration, allowing the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification enables the company to be recognized as a professional oncology medical institution with the capability to utilize innovative drugs and medical devices from Hong Kong and Macao, thereby broadening its business scope [1] - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, enhancing clinical diagnosis and treatment levels, and accelerating alignment with international medical standards [1] Group 2 - The introduction of cutting-edge drugs and medical devices is expected to optimize oncology treatment plans and improve patient service experience and treatment outcomes [1] - The company aims to provide urgently needed medications for more oncology patients, reinforcing its competitive edge in the oncology medical field [1]

Core Viewpoint - The company, Meizhong Jiahe (02453.HK), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macau Medical Device and Drug Access" list, enhancing its capabilities in oncology treatment and expanding its competitive edge in the market [1] Group 1 - The approval was granted by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration, allowing the hospital to import and use urgently needed clinical drugs and advanced medical devices that are already available in Hong Kong and Macau but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the ability to utilize innovative drugs and devices from Hong Kong and Macau, thereby broadening its business scope and creating a differentiated competitive advantage in the oncology sector [1] - The initiative will facilitate deeper integration with Hong Kong and Macau's medical resources, enhancing clinical treatment levels and research capabilities, while also optimizing cancer treatment plans and aligning with international medical standards [1]

本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 公司獲批進入「港澳藥械通」指定醫療機構名單 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院於2025年12月8日，獲廣東省 衛生健康委員會與廣東省藥品監督管理局批准進入粵港澳大灣區「港澳藥械通」指 定醫療機構名單。 「港澳藥械通」是《粵港澳大灣區藥品醫療器械監管創新發展工作方案》的核心落地 舉措，進入名單的粵港澳大灣區的指定醫療機構，可經審批進口使用粵港澳大灣 區專項醫藥政策，允許指定醫療機構經審批使用港澳已上市的臨床急需藥品及具 有先進性的醫療器械。 本 ...

美中嘉和醫學技術發展集團股份有限公司 董事會議事規則 第一章 總則 第一條 為了進一步明確美中嘉和醫學技術發展集團股份有限公司（以下簡稱「公 司」）董事會的職權範圍，規範董事會內部機構及運作程序，健全董事會的議事和 科學決策程序，充分發揮董事會的經營決策中心作用，根據《中華人民共和國公 司法》（以下簡稱「《公司法》」）、《中華人民共和國證券法》《上市公司治理準則》 《境內企業境外發行證券和上市管理試行辦法》《香港聯合交易所有限公司證券上 市規則》（以下簡稱「《香港上市規則》」）等其他有關法律法規的規定及《美中嘉和 醫學技術發展集團股份有限公司章程》（以下簡稱「公司章程」），制定本規則。 第二章 董事會的組成及職權 第二條 公司設董事會，對股東會負責。 第三條 董事會由9名董事組成，其中3名為獨立非執行董事，1名為職工董事。 第四條 董事會設董事長1人，可設副董事長。董事長和副董事長由董事會以全 體董事的過半數選舉產生。 第五條 董事會行使下列職權： 1 （一） 召集股東會，並向股東會報告工作； （二） 執行股東會的決議； （三） 決定公司的經營計劃和投資方案； （四） 制訂公司的利潤分配方案和彌補虧損方案； ...

美中嘉和醫學技術發展集團股份有限公司 股東會議事規則 第一章 總則 第一條 為了維護全體股東的合法權益，規範美中嘉和醫學技術發展集團 股份有限公司（以下簡稱「公司」）的行為，保證公司股東會規範、高效運作，確 保股東平等、有效地行使權利，根據《中華人民共和國公司法》（以下簡稱「《公司 法》」）、《中華人民共和國證券法》（以下簡稱「《證券法》」）、《香港聯合交易所有限 公司證券上市規則》（以下簡稱「香港上市規則」）《境內企業境外發行證券和上市 管理試行辦法》等其他有關規定以及《美中嘉和醫學技術發展集團股份有限公司章 程》（以下簡稱「公司章程」），制定本規則。 第二條 公司應當嚴格按照法律、行政法規、公司章程和本規則的相關規 定召開股東會，保證股東能夠依法行使權利。公司董事會應當切實履行職責，認 真、按時組織股東會。公司全體董事應當勤勉盡責，確保股東會正常召開和依法 行使職權。 第三條 股東會應當在《公司法》和公司章程規定的範圍內行使職權。 第四條 股東會分為年度股東會和臨時股東會。年度股東會每年召開1次， 應當於上一個會計年度結束後的6個月內舉行；臨時股東會不定期召開。 有下列情形之一的，公司在事實發生之日起2個 ...